ASCO 2020 Highlights

DAIICHI SANKYO CO., LTD.

Sunao Manabe
President and CEO

June 2020
Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

DS-8201 was approved and launched in US and Japan
Strategic alliance with AstraZeneca is strongly progressing for both development/promotion
**DS-8201: Breast and Gastric Cancers**

*Breast cancer*

- Launched Enhertu in US and JP for 3L treatment
- Phase 3 studies, DESTINY-Breast02, 03, 04, are on track
- Earlier line development is under consideration

*Gastric cancer*

- Positive results from pivotal phase 2 study
  - ORR: 42.9%
  - Published in NEJM
- Apr. 2020: sNDA submitted in JP (SAKIGAKE)
- May 2020: BTD/ODD in US

---

3L: 3rd line, BTD: breakthrough therapy designation, ODD: orphan drug designation
DS-8201: Progress of Lung and Colorectal Cancers

**Lung cancer**
- Favorable results in HER2 mutation cohort
  - ORR: 61.9%
- May 2020: BTD in US

**Colorectal cancer**
- Favorable results in HER2 positive cohort
  - ORR: 45.3%

**DS-8201 has the potential to become new treatment options for these cancers**

BTD: breakthrough therapy designations
Progress of DS-1062 and U3-1402

**DS-1062**

- Phase 1 interim data was presented as poster
- Next step is under consideration
  - Pivotal study for NSCLC w/o mutation (post IO/platinum)
  - NSCLC with mutation (post TKIs and platinum)
  - Combo studies with PD-1/PD-L1 for NSCLC
  - **Clinical trial collaboration with Merck for pembrolizumab combo**

**U3-1402**

- EGFRm NSCLC phase 1 trial data is planned to be presented at ESMO 2020
- Breast cancer development plan is under consideration
- Next step is under consideration
  - Pivotal study for NSCLC with EGFR mutation
  - Colorectal cancer

**Development is progressing steadily**

NSCLC: non-small cell lung cancer
3 and Alpha: R&D Strategy Change

3 and Alpha strategy
- Allocate financial/human resources with priority to maximize the 3 ADCs
- Focus on activities with potential to change the current SOCs for Alpha

3 ADC
- DS-8201
- DS-1062
- U3-1402

Alpha
- Oncology
- Specialty Medicine
- Vaccines

SOC: standard of care
3 ADCs: Growth Drivers of Our Business

**Business growth scenario has become clearer as 3 ADCs progress steadily**

**US Business**
- **Business Challenge**
  - Lack of products to drive future growth
- 3 ADCs, particularly Enhertu, are core pillars for re-growth of US business

**Europe and ASCA**
- **Business Challenge**
  - Limited opportunity for future growth with thin portfolio focused on Lixiana
- 3 ADCs will expand the portfolio, and will accelerate future growth
Core Pillars for 5-year Business Plan (FY2021-FY2025)

**Enhertu/DS-8201**
- Maximize product value
  - Expand indication
  - Expand marketed countries

**DS-1062/U3-1402**
- Optimize development strategies
  - Accelerate R&D activities
  - Potential utilization of external resources

**New Modality for Sustainable Growth**
- Create New Modality PJs
  - Next generation ADC, Onco-virus
  - Gene therapy, Nucleic Acid, Cell therapy

- Optimize R&D resource allocation to maximize future business growth
- Our new 5-year business plan will be announced in March - April 2021
ASCO 2020 Highlights

DAIICHI SANKYO CO., LTD.

Antoine Yver MD Msc
Global Head Oncology R&D

June 2020
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan
6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
Today’s Agenda

1. Introduction
   - DS-8201: The Value
   - DS-8201: The Data
   - DS-8201: The Plan
   - DS-1062: The Data & The Plan

6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
Daiichi Sankyo R&D Journey

Steady and strong progress

2016

Cancer Enterprise Strategy
- Accelerated DS-8201 and scale of manufacturing (300M$ CAPEX)
- Predicted 2019 crunch point for CE, needing ~100% R&D Unit Budget

2017

R&D Strategy and Cancer Enterprise 2025
- ‘7 in 8’ CE 2025
- Enhanced CE allocation of R&D resources

2018

ADC Franchise Strategy
- Highlighted the scope of opportunity offered by the DXd platform
- Operating model to maximize the ADC franchise value
- Validated ADC strategy with AZ agreement

2019

“3 and Alpha” Strategy
- Prioritize investment & resources to 3 ADCs
- Alpha focuses on changing SOCs

2020

Delivery
- Substantial value
- Fascinating new science
- Continued transformation
Creating value

New drug approvals since ASCO 2019

- ENHERTU® (US, JP)
- TURALIO® (US)
- VANFLYTA® (JP)

Fascinating new science

on the role of receptors in ADC pharmacology

- HER3 (as discussed during R&D Day Dec 2019)
- HER2 in NSCLC and colorectal cancer
- TROP2 in NSCLC
2020: Year of Continued Transformation to Support Delivery

Transformation of Global Development Operations

R&D forward-looking budget
16% YoY increase, directly funding ADC demand

<table>
<thead>
<tr>
<th>(Bn JPY)</th>
<th>FY2019 Results</th>
<th>FY2020 Forecast</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D expenses</td>
<td>197.5</td>
<td>228.0</td>
<td>30.5</td>
</tr>
</tbody>
</table>

Coalition with Syneos Health: an exceptional collaboration

Alpha Strategy: build on unique DS science, to secure 2030+

Scale and agility to meet biologics demand
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan
6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
1st approval after **short 113 days review**

**Outstanding launch** sequence

**Clear indication**: not specifying prior treatment with T-DM1

With the recent approval of tucatinib, the 2nd line and beyond treatment sequence in HER2 metastatic breast cancer has significantly evolved

- DESTINY-Breast03 study (Ph 3 vs. T-DM1) will further establish the pivotal role of ENHERTU
- Gating combination trials (to support 1st and 2nd line testing) underway/preparation
- Clear positive effect of ILD Safe Use measures

**HER2+ Gastric Cancer Breakthrough Designation** (May ‘20)

**HER2 mutant NSCLC Breakthrough Designation** (May ‘20)
DS-8201 | The Value

Japan

- 1st approval March 2020 (6-month review, breast cancer)
- 2nd submission sJNDA, for gastric cancer under SAKIGAKE designation, late April 2020 – expect 6-month review
- Early access program for gastric cancer launched in Japan

EU

- Breast cancer submission expected in 1HFY2020
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan
6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)


On behalf of the DESTINY-Gastric01 Investigators

**DESTINY-Gastric01**

An open-label, multicenter, randomized phase 2 study

- T-DXd is an antibody-drug conjugate consisting of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload
- Previously, T-DXd 5.4 or 6.4 mg/kg in a phase 1 study demonstrated an ORR of 43.2% and median PFS of 5.6 months in 44 patients with HER2-positive gastric or GEJ cancer previously treated with trastuzumab (NCT02564900)\(^1\)
- We present the results for the primary cohort of DESTINY-Gastric01 (NCT03329690)


---

**Primary endpoint**
- ORR by ICR

**Secondary endpoints**
- OS, DOR, PFS, confirmed ORR, safety

---

**Patients**
- HER2-expressing advanced gastric or GEJ adenocarcinoma
- ≥ 2 Prior regimens; must include fluoropyrimidine and a platinum agent

**Exploratory cohorts (HER2 low)**
- Anti-HER2 treatment naive
  - Cohort 1: HER2 (IHC 2+/ISH–)
    - T-DXd (N = 20)
  - Cohort 2: HER2 (IHC 1+)
    - T-DXd (N = 20)

*OS was a key secondary endpoint to be statistically evaluated hierarchically if the primary endpoint was statistically significant (Familywise type I error was controlled at 0.05 for ORR and OS)

- 187 patients were randomized (T-DXd, n = 125; PC, n = 62)
- 76% of patients had HER2 IHC 3+
- The median number of prior systemic therapies was 2 (range, 2-9)
- 86% previously received taxanes, 72% ramucirumab, and 33% anti-PD1/-PD–L1
- At data cut-off (November 8, 2019), 22.4% and 4.8% of patients in the T-DXd and PC arms remained on treatment
DESTINY-Gastric01

Primary Endpoint: ORR

<table>
<thead>
<tr>
<th></th>
<th>T-DXd (n = 119)</th>
<th>PC (n = 56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR by ICR (CR + PR)</td>
<td>51.3% (n = 61)</td>
<td>14.3% (n = 8)</td>
</tr>
<tr>
<td></td>
<td>95% CI, 41.9-60.5; P &lt; .0001</td>
<td>95% CI, 6.4-26.2</td>
</tr>
<tr>
<td>Confirmed ORR by ICR (CR + PR)</td>
<td>42.9% (n = 51)</td>
<td>12.5% (n = 7)</td>
</tr>
<tr>
<td></td>
<td>95% CI, 33.8-52.3</td>
<td>95% CI, 5.2-24.1</td>
</tr>
<tr>
<td>CR</td>
<td>8.4% (n = 10)</td>
<td>0</td>
</tr>
<tr>
<td>PR</td>
<td>34.5% (n = 41)</td>
<td>12.5% (n = 7)</td>
</tr>
<tr>
<td>SD</td>
<td>42.9% (n = 51)</td>
<td>50.0% (n = 28)</td>
</tr>
<tr>
<td>PD</td>
<td>11.8% (n = 14)</td>
<td>30.4% (n = 17)</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>2.5% (n = 3)</td>
<td>7.1% (n = 4)</td>
</tr>
<tr>
<td>Confirmed DCR (CR + PR + SD)</td>
<td>85.7% (n = 102)</td>
<td>62.5% (n = 35)</td>
</tr>
<tr>
<td></td>
<td>95% CI, 78.1-91.5</td>
<td>95% CI, 48.5-75.1</td>
</tr>
<tr>
<td>Median confirmed DOR</td>
<td><strong>11.3 months</strong></td>
<td><strong>3.9 months</strong></td>
</tr>
<tr>
<td></td>
<td>95% CI, 5.6-NE</td>
<td>95% CI, 3.0-4.9</td>
</tr>
</tbody>
</table>

Includes data for the response evaluable set: all randomized patients who received ≥1 dose of study drug and had measurable tumors based on independent central review at baseline.

Best Percentage Change from Baseline in Tumor Size

Line at 20% indicates progressive disease; line at −30% indicates partial response. Includes patients who had both baseline and postbaseline target lesion assessments by independent central review in both treatment arms.

Presented by: Dr. Kohei Shitara; National Cancer Center Hospital East, Chiba, Japan; kshitara@east.ncc.go.jp
DESTINY-Gastric01

Overall and Progression-Free Survival

**Overall Survival**

- **Events/n**
  - T-DXd: 62/125
  - Physician’s choice: 39/62

- **Median**
  - T-DXd: 12.5 months (95% CI, 9.6-14.3)
  - Physician’s choice: 8.4 months (95% CI, 6.9-10.7)

- **HR, 0.59 (95% CI, 0.39-0.88)**
  - P = .0097

(prespecified O’Brien-Fleming boundary, P = .0202)

**Progression-Free Survival**

- **Events/n**
  - T-DXd: 73/125
  - Physician’s choice: 36/62

- **Median**
  - T-DXd: 5.6 months (95% CI, 4.3-6.9)
  - Physician’s choice: 3.5 months (95% CI, 2.0-4.3)

- **HR, 0.47 (95% CI, 0.31-0.71)**

No. at risk

<table>
<thead>
<tr>
<th>Months</th>
<th>T-DXd</th>
<th>Physician’s choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>125</td>
<td>62</td>
</tr>
<tr>
<td>3</td>
<td>115</td>
<td>54</td>
</tr>
<tr>
<td>6</td>
<td>88</td>
<td>37</td>
</tr>
<tr>
<td>9</td>
<td>54</td>
<td>19</td>
</tr>
<tr>
<td>12</td>
<td>33</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td>14</td>
<td>2</td>
</tr>
<tr>
<td>18</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>21</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>24</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

No. at risk

<table>
<thead>
<tr>
<th>Months</th>
<th>T-DXd</th>
<th>Physician’s choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>125</td>
<td>62</td>
</tr>
<tr>
<td>3</td>
<td>82</td>
<td>19</td>
</tr>
<tr>
<td>6</td>
<td>35</td>
<td>5</td>
</tr>
<tr>
<td>9</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>12</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>15</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>18</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>21</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>24</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
DESTINY-Gastric01

Safety Summary

- There was 1 drug-related death due to pneumonia with T-DXd and none with PC
- 12 patients (9.6%) had T-DXd-related ILD/pneumonitis as determined by an independent adjudication committee
  - Median time to first onset, 84.5 days (range, 36-638 days)
  - Most were grade 1 or 2 (grade 1, n=3; grade 2, n=6; grade 3, n=2; grade 4, n=1; no grade 5 events)

TEAEs associated with:

<table>
<thead>
<tr>
<th></th>
<th>T-DXd (n = 125)</th>
<th>PC (n = 62)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug discontinuation</td>
<td>15.2%</td>
<td>6.5%</td>
</tr>
<tr>
<td>Dose reduction</td>
<td>32.0%</td>
<td>33.9%</td>
</tr>
<tr>
<td>Dose interruption</td>
<td>62.4%</td>
<td>37.1%</td>
</tr>
</tbody>
</table>

Patients, %

- Nausea
- Neutropenia
- Decreased appetite
- Anemia
- Thrombocytopenia
- WBC decreased
- Malaise
- Diarrhea
- Vomiting
- Constipation
- Pyrexia
- Alopecia
- Fatigue
- Lymphopenia

Grade 1 or 2
Grade ≥ 3

T-DXd
PC

Presented by: Dr Kohei Shitara; National Cancer Center Hospital East, Chiba, Japan; kshitara@east.ncc.go.jp
Trastuzumab Deruxtecan (T-DXd; DS-8201) in Patients With HER2-Mutated Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

Egbert F. Smit, Kazuhiko Nakagawa, Misako Nagasaka, Enriqueta Felip, Yasushi Goto, Bob T. Li, Jose M. Pacheco, Haruyasu Murakami, Fabrice Barlesi, Andreas Saltos, Maurice Perol, Hibiki Udagawa, Kapil Saxena, Ryota Shiga, Ferdinand Guevara, Suddhasatta Acharyya, Javad Shahidi, David Planchard, Pasi A. Jänne

On behalf of the DESTINY-Lung01 investigators
DESTINY-Lung01 Study Design
An open-label, multicenter, phase 2 study (NCT03505710)

Patients
• Unresectable/metastatic nonsquamous NSCLC
• Relapsed/refractory to standard treatment
• HER2-expressing or HER2-activating mutation
• No prior HER2-targeted therapy, except pan-HER TKIs

Primary endpoint
• Confirmed ORR by independent central review

Cohort 1 (n = 42)
HER2 expressing (IHC 3+ or IHC 2+)

Cohort 2 (n = 42)
HER2 mutated
T-DXd 6.4 mg/kg q3w

Data cutoff: November 25, 2019
• 45.2% of patients (19/42) in Cohort 2 remained on treatment
• 54.8% discontinued, primarily for progressive disease and adverse events (21.4% each)

a Based on local assessment of archival tissue.
## Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients (N = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), years</td>
<td>63.0 (34-83)</td>
</tr>
<tr>
<td>&lt; 65 years, %</td>
<td>59.5</td>
</tr>
<tr>
<td>Female, %</td>
<td>64.3</td>
</tr>
<tr>
<td>Region, %</td>
<td></td>
</tr>
<tr>
<td>Asia / North America / Europe</td>
<td>35.7 / 31.0 / 33.3</td>
</tr>
<tr>
<td>ECOG performance status 0 / 1, %</td>
<td>23.8 / 76.2</td>
</tr>
<tr>
<td>HER2 mutation, %</td>
<td></td>
</tr>
<tr>
<td>Kinase domain</td>
<td>90.5</td>
</tr>
<tr>
<td>Extracellular domain</td>
<td>4.8</td>
</tr>
<tr>
<td>Not reported</td>
<td>4.8</td>
</tr>
<tr>
<td>Presence of CNS metastases, %</td>
<td>45.2</td>
</tr>
</tbody>
</table>
## DESTINY-Lung01 HER2-Mutated NSCLC

### Prior Treatments

**Median prior lines of treatment: 2 (range, 1-6)**

<table>
<thead>
<tr>
<th>Prior Treatment, %</th>
<th>Patients (N = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platinum-based therapy</td>
<td>90.5</td>
</tr>
<tr>
<td>Anti–PD-1 or –PD-L1 inhibitor</td>
<td>54.8</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>19.0</td>
</tr>
</tbody>
</table>

- 3 patients received prior poziotinib, 2 received afatinib, and 1 received mobocertinib
# Efficacy Results

<table>
<thead>
<tr>
<th>Confirmed ORR by ICR</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients (N = 42)</td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>61.9% (n = 26)</td>
<td>(95% CI, 45.6%-76.4%)</td>
</tr>
<tr>
<td>PR</td>
<td>2.4% (n = 1)</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>59.5% (n = 25)</td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td>28.6% (n = 12)</td>
<td></td>
</tr>
<tr>
<td>Not evaluable</td>
<td>4.8% (n = 2)</td>
<td></td>
</tr>
</tbody>
</table>

- **Disease control rate**: 90.5% (95% CI, 77.4%-97.3%)

- **Duration of response, median**: Not reached (95% CI, 5.3 months-NE)

- **PFS, median**: 14.0 mo (95% CI, 6.4-14.0 months)
DESTINY-Lung01 HER2-Mutated NSCLC

Best Change in Tumor Size

Based on independent central review. Baseline is last measurement taken before enrollment. Shown is best (minimum) percent change from baseline in the sum of diameters for all target lesions.

One patient was missing a baseline assessment and 2 additional patients were missing post-baseline assessments.

$n = 39^a$

---

$a$ One patient was missing a baseline assessment and 2 additional patients were missing post-baseline assessments.
DESTINY-Lung01 HER2-Mutated NSCLC

Progression-Free and Overall Survival

**Progression-Free Survival (N = 42)*

Median: 14.0 months (95% CI, 6.4-14.0)

**Overall Survival (N = 42)**

Median: Not reached (95% CI, 11.8-NE)

---

*Patients were censored if they discontinued treatment; the median is estimated by Kaplan-Meier analysis.

Median follow-up, 8.0 months (range, 1.4-14.2 months). Dashed lines indicate upper and lower 95% CI.
DESTINY-Lung01 HER2-Mutated NSCLC

Overall Safety Summary

- Median treatment duration was 7.76 months (range, 0.7-14.3 months)
- The most common TEAEs associated with dose reduction were fatigue (11.9%) and nausea (9.5%)\(^c\)
- The most common TEAEs associated with dose interruption were decreased neutrophil count (19.0%) and lung infection (7.1%)\(^c\)
- There were 5 patients with TEAEs associated with death\(^d\); none were related to treatment

<table>
<thead>
<tr>
<th>Type of Adverse Event, n (%)(^a)</th>
<th>Patients (N = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAE Drug-related</td>
<td>42 (100)</td>
</tr>
<tr>
<td>TEAE grade ≥ 3 Drug-related</td>
<td>27 (64.3)</td>
</tr>
<tr>
<td>Serious TEAE Drug-related</td>
<td>14 (33.3)</td>
</tr>
<tr>
<td>Dose adjustments</td>
<td></td>
</tr>
<tr>
<td>TEAE associated with discontinuation(^b) Drug-related</td>
<td>10 (23.8)</td>
</tr>
<tr>
<td>TEAE associated with dose reduction Drug-related</td>
<td>16 (38.1)</td>
</tr>
<tr>
<td>TEAE associated with dose interruption Drug-related</td>
<td>25 (59.5)</td>
</tr>
</tbody>
</table>

\(^a\) Relationship to study drug was determined by the treating investigator. \(^b\) Each of the following TEAEs was associated with treatment discontinuation: pneumonitis (n=4), delirium, ILD, diarrhea, disease progression, ejection fraction decreased, weight decreased (n=1 each). \(^c\) TEAEs occurring in > 2 patients are listed. \(^d\) Each of the following TEAEs was associated with a fatal outcome: seizure, delirium, disease progression (n=2), and pneumonia (fungal).
DESTINY-Lung01 HER2-Mutated NSCLC

Treatment-Emergent Adverse Events in >15% of Patients

- Nausea
- Alopecia
- Anemia
- Decreased appetite
- Neutrophil count decreased
- Vomiting
- Diarrhea
- Weight decreased
- Constipation
- Fatigue
- WBC count decreased
- AST increased
- Malaise
- Lung infection
- Pyrexia

Patients (%)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Patients (N = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophil count decreased</td>
<td>Grade 1 or 2</td>
</tr>
<tr>
<td></td>
<td>Grade ≥3</td>
</tr>
</tbody>
</table>

* 2 patients had febrile neutropenia; grade ≥3 neutrophil count decreased, 26.2%.
DESTINY-Lung01 HER2-Mutated NSCLC

AEs of Special Interest: Interstitial Lung Disease (ILD)

- Median time to onset of investigator-reported ILD was at 86 days (range, 41-255 days)
- 4 patients had drug withdrawn and 1 had drug interrupted
- All patients received steroid treatment
- 2 patients recovered, 1 recovered with sequelae, 1 was recovering, and 1 had not recovered by data-cutoff
- No grade 5 ILD was observed in this cohort

<table>
<thead>
<tr>
<th>n (%)</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Grade 5</th>
<th>Any Grade/Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interstitial lung disease</td>
<td>0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>5 (11.9)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>5 (11.9)</td>
</tr>
</tbody>
</table>

Drug-related; ILD was determined by an Independent ILD Adjudication Committee based on 44 preferred terms.
<sup>a</sup> 1 additional case of potential grade 1 ILD is pending adjudication.
A Phase 2, Multicenter, Open-Label Study of Trastuzumab Deruxtecan (T-DXd; DS-8201) in Patients With HER2-Expressing Metastatic Colorectal Cancer: DESTINY-CRC01


On behalf of the DESTINY-CRC01 investigators
DESTINY-CRC01 Study Design

An open-label, multicenter, phase 2 study (NCT03384940)

Patients
- Unresectable and/or metastatic CRC
- HER2 expressing (central confirmation)
- RAS/BRAF wild type
- ≥2 prior regimens
- Prior anti-HER2 treatment was allowed
- Excluded patients with a history of or current/suspected interstitial lung disease

Primary endpoint
- Confirmed ORR by independent central review (ICR) in Cohort A

Cohort A (n = 53)
HER2 Positive (IHC 3+ or IHC 2+/ISH+)

A futility monitoring was done after ≥20 patients in Cohort A had 12 weeks of follow-up to inform opening of Cohorts B and C

Cohort B (n = 7)
HER2 IHC 2+/ISH−

Cohort C (n = 18)
HER2 IHC 1+

Data cutoff: August 9, 2019
- 38.5% (30/78) remained on treatment
- 61.5% discontinued, primarily for progressive disease (41.0%) and clinical progression (9.0%)

T-DXd 6.4 mg/kg q3w
# Patient Baseline Characteristics

<table>
<thead>
<tr>
<th></th>
<th>HER2+ Cohort A (n = 53)</th>
<th>All Patients (N = 78)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), years</td>
<td>57.0 (27-79)</td>
<td>58.5 (27-79)</td>
</tr>
<tr>
<td>Female, %</td>
<td>52.8</td>
<td>47.4</td>
</tr>
<tr>
<td>Region, %</td>
<td>52.8 / 28.3 / 18.9</td>
<td>52.6 / 32.1 / 15.4</td>
</tr>
<tr>
<td>Europe / Asia / North America</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG performance status 0 / 1 / 2, %</td>
<td>69.8 / 30.2 / 0</td>
<td>62.8 / 35.9 / 1.3</td>
</tr>
<tr>
<td>Sum of target lesions, median, cm</td>
<td>8.4</td>
<td>8.8</td>
</tr>
<tr>
<td>Primary tumor site, left / right, %</td>
<td>88.7 / 11.3</td>
<td>89.7 / 10.3</td>
</tr>
<tr>
<td>Microsatellite stable / unknown, %</td>
<td>81.1 / 18.9</td>
<td>79.5 / 20.5</td>
</tr>
<tr>
<td>RAS wild type, %</td>
<td>98.1</td>
<td>98.7</td>
</tr>
<tr>
<td>BRAF wild type, %</td>
<td>100</td>
<td>98.7</td>
</tr>
<tr>
<td>HER2 status, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IHC 3+ / IHC 2+; ISH+</td>
<td>75.5 / 24.5</td>
<td>51.3 / 16.7</td>
</tr>
<tr>
<td>IHC 2+ / IHC 1+</td>
<td>0 / 0</td>
<td>25.6 / 23.1</td>
</tr>
</tbody>
</table>

---

a Left: rectum, sigmoidal, descending; Right: cecum, ascending, transverse. b By local assessment. c 1 patient had an NRAS mutation. d By central assessment. Sums may not total 100% due to rounding.
**DESTINY-CRC01**

## Prior Treatments

Median prior lines of cancer treatment: 4 (range, 2-11)\(^a\)

<table>
<thead>
<tr>
<th>Prior Treatment, %</th>
<th>HER2+ Cohort A (n = 53)</th>
<th>All Patients (N = 78)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irinotecan</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Fluorouracil / capecitabine</td>
<td>100 / 54.7</td>
<td>98.7 / 53.8</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Cetuximab or panitumumab</td>
<td>100</td>
<td>98.7</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>75.5</td>
<td>79.5</td>
</tr>
<tr>
<td>Prior anti-HER2 agents</td>
<td>30.2</td>
<td>20.5</td>
</tr>
</tbody>
</table>

- Prior anti-HER2 agents in Cohort A included pertuzumab (24.5%), trastuzumab (22.6%), T-DM1 (5.7%), lapatinib (5.7%), and tucatinib (1.9%)

\(^a\) Includes all prior treatments in the adjuvant and metastatic settings.
<table>
<thead>
<tr>
<th>Confirmed ORR by ICR</th>
<th>HER2+ Cohort A (N = 53) (95% CI, 31.6%-59.6%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>45.3% (n = 24)</td>
</tr>
<tr>
<td></td>
<td>1.9% (n = 1)</td>
</tr>
<tr>
<td></td>
<td>43.4% (n = 23)</td>
</tr>
<tr>
<td></td>
<td>37.7% (n = 20)</td>
</tr>
<tr>
<td></td>
<td>9.4% (n = 5)</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>7.5% (n = 4)(^{a})</td>
</tr>
<tr>
<td>Disease control rate</td>
<td>83.0% (95% CI, 70.2%-91.9%)</td>
</tr>
<tr>
<td>Duration of response</td>
<td>Not reached (95% CI, 4.2 months-NE)</td>
</tr>
</tbody>
</table>

\(^{a}\) Patients were missing postbaseline scans.
Median study duration, 5.0 months (range, 0.6-10.5 months). There were no confirmed responses by ICR in Cohort B or C.
DESTINY-CRC01

Best Change in Tumor Size

HER2+ Cohort A (N = 53)

- IHC3+
- IHC2+/ISH+
- Prior anti-HER2 treatment

Best % Change From Baseline in the Sum of Diameters of Measurable Tumors
DESTINY-CRC01

Tumor Shrinkage Over Time

HER2+ Cohort A (N = 53)

% Change in Sum of Diameters from Baseline

Time (Months) from First Dose of Study Drug
DESTINY-CRC01

Progression-Free and Overall Survival

**Progression-Free Survival (N = 53)**

*Median:* 6.9 months

(95% CI, 4.1-NE)

**Overall Survival (N = 53)**

*Median:* Not reached

(overall 95% CI, 0.74-NE)

Median follow-up for OS was 5.4 month (range, 1.2-11.8 months).
### Overall Safety Summary

<table>
<thead>
<tr>
<th>Type of Adverse Event, n (%)$^a$</th>
<th>HER2+ Cohort A (n = 53)</th>
<th>All Patients (N = 78)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAE</td>
<td>53 (100)</td>
<td>78 (100)</td>
</tr>
<tr>
<td>Drug-related</td>
<td>51 (96.2)</td>
<td>73 (93.6)</td>
</tr>
<tr>
<td>TEAE grade ≥3</td>
<td>32 (60.4)</td>
<td>48 (61.5)</td>
</tr>
<tr>
<td>Drug-related</td>
<td>27 (50.9)</td>
<td>38 (48.7)</td>
</tr>
<tr>
<td>Serious TEAE</td>
<td>18 (34.0)</td>
<td>26 (33.3)</td>
</tr>
<tr>
<td>Drug-related</td>
<td>12 (22.6)</td>
<td>14 (17.9)</td>
</tr>
<tr>
<td>Dose adjustments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEAE associated with discontinuation</td>
<td>5 (9.4)</td>
<td>7 (9.0)</td>
</tr>
<tr>
<td>Drug-related</td>
<td>2 (3.8)</td>
<td>2 (2.6)</td>
</tr>
<tr>
<td>TEAE associated with dose reduction</td>
<td>11 (20.8)</td>
<td>15 (19.2)</td>
</tr>
<tr>
<td>Drug-related</td>
<td>10 (18.9)</td>
<td>14 (17.9)</td>
</tr>
<tr>
<td>TEAE associated with dose interruption</td>
<td>20 (37.7)</td>
<td>27 (34.6)</td>
</tr>
<tr>
<td>Drug-related</td>
<td>15 (28.3)</td>
<td>19 (24.4)</td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEAE associated with death$^b$</td>
<td>5 (9.4)</td>
<td>7 (9.0)</td>
</tr>
<tr>
<td>Drug-related</td>
<td>2 (3.8)</td>
<td>2 (2.6)</td>
</tr>
</tbody>
</table>

$^a$TEAE, treatment-emergent adverse event. $^b$Relationship to study drug was determined by the treating investigator. $^b$Each of the following TEAEs was associated with a fatal outcome: sepsis, meningism, disease progression (n = 2), general physical health deterioration (all unrelated to T-DXd), interstitial lung disease, and pneumonitis (both related to T-DXd).

- **Median treatment duration**
  - HER2+ patients, 4.8 months (range, 1-11)
  - All patients, 3.5 months (range, 1-11)

- **Causes of death related to study drug according to investigator assessment (n = 2) included pneumonitis (n = 1) andILD (n = 1), both in HER2+ Cohort A**
DESTINY-CRC01

Treatment-Emergent Adverse Events in >15% of Patients

- Nausea
- Anemia
- Neutrophil count decreased
- Fatigue
- Decreased appetite
- Platelet count decreased
- Vomiting
- Diarrhea
- Alopecia
- Hypokalemia
- WBC count decreased

![Bar Chart]

All Patients (N = 78)

- Grade 1 & 2
- Grade ≥3

![Bar Chart]

- Neutrophil count decreased, 25.6%; no patients had febrile neutropenia.
DESTINY-CRC01

AEs of Special Interest: Interstitial Lung Disease

Drug related; ILD was determined by an Independent ILD Adjudication Committee based on 44 preferred terms. One additional grade 5 ILD case in Cohort B was reported after the data cutoff. This case was adjudicated after data cutoff as drug-related ILD.

Among the 5 total events:
- Median time to investigator-reported onset was 80 days (range, 22-132)
- 5 of 5 patients with grade ≥ 2 ILD received corticosteroids
- 2 patients recovered, 1 did not recover (later died due to disease progression), and 2 died
- In the 2 fatal cases, onset was from 40-126 days, both received steroids as part of treatment, and death occurred 6-18 days after diagnosis

<table>
<thead>
<tr>
<th>Preferred Term, n (%)</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Grade 5</th>
<th>Any Grade/Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interstitial Lung Disease</td>
<td>0</td>
<td>2 (2.6)</td>
<td>1 (1.3)</td>
<td>0</td>
<td>2 (2.6)</td>
<td>5 (6.4)</td>
</tr>
</tbody>
</table>
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan
6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
Results from Collaboration with AstraZeneca

- **DS-8201**: significant increase in the number of trials
  - Before collaboration: **17 studies**
  - After collaboration: **43 studies**

- Expansion of I/O combo studies
  (adding DS-8201 cohort to IMFINZI® (durvalumab) combo studies conducted by AstraZeneca)
<table>
<thead>
<tr>
<th>Study Area</th>
<th>FY2020</th>
<th>FY2021</th>
<th>Under Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast HER2+</strong></td>
<td>DESTINY-Breast02 (3L)</td>
<td></td>
<td>Ph3 adjuvant</td>
</tr>
<tr>
<td></td>
<td>DESTINY-Breast03 (2L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ph 1/2 combo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ph3 Post neo-adjuvant</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ph 3 1L mono/combo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neo-adjuvant</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Breast HER2 low</strong></td>
<td>DESTINY-Breast04 (3L)</td>
<td></td>
<td>Ph3 post neo-adjuvant</td>
</tr>
<tr>
<td></td>
<td>BEGONIA (durvalumab combo, TNBC)</td>
<td></td>
<td>Ph3 neo-adjuvant</td>
</tr>
<tr>
<td></td>
<td>Ph1 Combo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ph3 1L mono (chemo naive)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ph3 1L mono (high risk)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastric</strong></td>
<td>DESTINY-Gastric02 (2L)</td>
<td></td>
<td>Ph3 HER2+ 1L</td>
</tr>
<tr>
<td></td>
<td>Ph1 DESTINY-Gastric03 (2L/1L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ph3 HER2+ 2L</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Study initiation points for 1H FY2020 are shown on quarterly basis. Study initiation points for 2H FY2020 are all shown as beginning of 2H. Study initiation points for FY2021 are all shown as beginning of FY2021.
## DS-8201 Clinical Development Plan

As of June 2020

<table>
<thead>
<tr>
<th>NSCLC</th>
<th>FY2020</th>
<th>FY2021</th>
<th>Under Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>DESTINY-Lung01 (2L)</td>
<td></td>
<td></td>
<td>◆ Ph3 stage III combo</td>
</tr>
<tr>
<td>HUDSON (durvalumab combo)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph3 HER2 mutation 1L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph1 HER2+ combo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph3 HER2+ 2L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph3 HER2+ 1L combo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CRC</th>
<th>FY2020</th>
<th>FY2021</th>
<th>Under Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>DESTINY-CRC01 (3L)</td>
<td></td>
<td></td>
<td>◆ Ph3 2L combo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>◆ Ph3 1L combo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>◆ Ph3 adjuvant combo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph2 3L mono</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph1/2 3L combo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Others</th>
<th>FY2020</th>
<th>FY2021</th>
<th>Under Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nivolumab combo (BC, Bladder)</td>
<td></td>
<td></td>
<td>◆ Ph2 ovarian mono/combo</td>
</tr>
<tr>
<td>Pembrolizumab combo (BC, NSCLC)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph2 HER2+ tumor agnostic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph2 HER2mutation tumor agnostic</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Study initiation points for 2H FY2020 are all shown as beginning of 2H FY2020.
Study initiation points for FY2021 are all shown as beginning of FY2021.
**DESTINY-Breast02 | HER2 MBC**
vs standard of care
- Event-driven final analysis projected 2HFY2021

**DESTINY-Breast03 | HER2 MBC**
vs T-DM1
- Event-driven interim analysis projected 1HFY2021

**DESTINY-Breast04 | HER2 low MBC**
vs standard of care
- Event-driven final analysis projected 2HFY2021

**I/O Combination**
currently 72 subjects in phase 1 combo studies with at least 2 separate market leading immune checkpoint inhibitors (64 subjects in expansion cohort)
- Data to be presented at future scientific meeting
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan
6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
Dose escalation and expansion from the phase 1 study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) ADC in patients with advanced NSCLC


On behalf of study investigators
Objective: To evaluate the maximum tolerated dose (MTD), safety, PK and activity of DS-1062 in patients with unselected advanced/metastatic NSCLC (NCT03401385/J101)

Phase 1

- Patients aged 18 (US) or 20 (Japan) years with metastatic/unresectable advanced NSCLC and
  - Disease relapsed from/refractory to standard treatment (or for which no standard treatment is available)
  - ECOG PS 0-1
  - Measurable disease per RECIST v1.1
- No selection for TROP2
  - Pretreatment tumor tissue required for retrospective analysis of TROP2 expression

Dose escalation

<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg/kg</td>
<td>(n ≈ 3-6)</td>
</tr>
<tr>
<td>8 mg/kg</td>
<td>(n ≈ 3-6)</td>
</tr>
<tr>
<td>6 mg/kg</td>
<td>(n ≈ 3-6)</td>
</tr>
<tr>
<td>4 mg/kg</td>
<td>(n ≈ 3-6)</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>(n ≈ 3-6)</td>
</tr>
<tr>
<td>1 mg/kg</td>
<td>(n ≈ 3-6)</td>
</tr>
<tr>
<td>0.5 mg/kg</td>
<td>(n ≈ 3-6)</td>
</tr>
<tr>
<td>0.27 mg/kg</td>
<td>(n ≈ 3-6)</td>
</tr>
</tbody>
</table>

Dose expansion

- Enrollment nearly complete of 50 subjects at 4 mg/kg, 50 subjects at 6 mg/kg, and 80 subjects at 8 mg/kg for robust dose justification
- Up to 40 patients each in 2 additional indications

*The 4.0 mg/kg and 6.0 mg/kg dose levels are being further evaluated for safety and efficacy.
ECOG, Eastern Cooperative Oncology Group; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PS, performance status; RDE, recommended dose for expansion; RECIST, Response Evaluation Criteria in Solid Tumors; TROP2, trophoblast cell-surface antigen 2; Q3W; once every 3 weeks; US, United States.
DS-1062 | Demographics and Baseline Characteristicsa

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Totalb N = 138</th>
<th>4 mg/kg (n = 12)</th>
<th>6 mg/kg (n = 20)</th>
<th>8 mg/kg (n = 76)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>66 (48)</td>
<td>8 (67)</td>
<td>8 (40)</td>
<td>37 (49)</td>
</tr>
<tr>
<td>Male</td>
<td>72 (52)</td>
<td>4 (33)</td>
<td>12 (60)</td>
<td>39 (51)</td>
</tr>
<tr>
<td>Median age (range), y</td>
<td>63 (28-84)</td>
<td>64 (38-76)</td>
<td>60 (47-75)</td>
<td>64 (31-84)</td>
</tr>
<tr>
<td>Country, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United States</td>
<td>110 (80)</td>
<td>11 (92)</td>
<td>16 (80)</td>
<td>62 (82)</td>
</tr>
<tr>
<td>Japan</td>
<td>28 (20)</td>
<td>1 (8)</td>
<td>4 (20)</td>
<td>14 (18)</td>
</tr>
<tr>
<td>ECOG PS, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>25 (18)</td>
<td>4 (33)</td>
<td>3 (15)</td>
<td>14 (18)</td>
</tr>
<tr>
<td>1</td>
<td>113 (82)</td>
<td>8 (67)</td>
<td>17 (85)</td>
<td>62 (82)</td>
</tr>
<tr>
<td>Prior Line of therapy,c n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>51 (37)</td>
<td>6 (50)</td>
<td>8 (40)</td>
<td>29 (38)</td>
</tr>
<tr>
<td>≥3</td>
<td><strong>87 (63)</strong></td>
<td>6 (50)</td>
<td>12 (60)</td>
<td>47 (62)</td>
</tr>
<tr>
<td>Previous systemic treatment, n (%)</td>
<td>137 (99)</td>
<td>12 (100)</td>
<td>20 (100)</td>
<td>75 (99)</td>
</tr>
<tr>
<td>Immune checkpoint inhibitors</td>
<td><strong>121 (88)</strong></td>
<td>12 (100)</td>
<td>16 (80)</td>
<td>66 (87)</td>
</tr>
<tr>
<td>Platinum</td>
<td><strong>126 (91)</strong></td>
<td>11 (92)</td>
<td>18 (90)</td>
<td>67 (88)</td>
</tr>
<tr>
<td>TKIs</td>
<td>31 (22)</td>
<td>3 (25)</td>
<td>4 (20)</td>
<td>13 (77)</td>
</tr>
<tr>
<td>EGFR alterations, n (%)</td>
<td>22 (16)</td>
<td>0</td>
<td>2 (10)</td>
<td>13 (17)</td>
</tr>
<tr>
<td>ALK fusions, n (%)</td>
<td>3 (2)</td>
<td>1 (8)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*aPatients may have received more than 1 previous systemic treatment; 1 patient did not have a record of prior systemic treatment as of data cutoff date.

*bIncludes patients at all dose levels.

*cPatients may have received more than 1 previous systemic treatment. One patient did not have a record of prior systemic treatment.

ECOG, Eastern Cooperative Oncology Group; PS, performance status; TKI, tyrosine kinase inhibitor.

- Median treatment duration at data cut-off (Mar. 4, 2020): 2 cycles (1-21)
- 25% dose interruptions, 22% reductions
- 59% discontinued treatment (31% progressive disease)
## DS-1062 | Safety Results

- **MTD:** 8 mg/kg  
  (2 DLTs at 10 mg/kg: 1 mucosal inflammation [grade 3], 1 stomatitis [grade 3])

- **TEAEs led to DS-1062 withdrawal in 7 patients**  
  (5%)

- **SAE in 20 patients (15%)**

- **8 ILD events (5.8%) adjudicated as treatment related**  
  (1 grade 1, 4 grade 2, 1 grade 3, 2 grade 5 i.e., 1.45%, onset at cycle 2 and 3)

### Patients treated with DS-1062  
(N = 138)

<table>
<thead>
<tr>
<th>TEAE in ≥15% subjects</th>
<th>All grades, n (%)</th>
<th>Grade ≥3, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAE</td>
<td>129 (94)</td>
<td>62 (45)</td>
</tr>
<tr>
<td>TEAEs in ≥15% of patients, by preferred term</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>60 (44)</td>
<td>0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>56 (41)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>47 (34)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>46 (33)</td>
<td>0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>37 (27)</td>
<td>0</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>31 (23)</td>
<td>0</td>
</tr>
<tr>
<td>Infusion-related reaction</td>
<td>29 (21)</td>
<td>0</td>
</tr>
<tr>
<td>Anemia</td>
<td>26 (19)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Constipation</td>
<td>26 (19)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Cough</td>
<td>26 (19)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Mucosal inflammation</td>
<td>25 (18)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Rash</td>
<td>25 (18)</td>
<td>0</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>23 (17)</td>
<td>6 (4)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>20 (15)</td>
<td>0</td>
</tr>
</tbody>
</table>

TEAE, treatment-emergent adverse event.
DS-1062 | Efficacy Results

Best Overall Tumor Response by Blinded Independent Central Review (BICR)

<table>
<thead>
<tr>
<th>DS-1062 dose, mg/kg</th>
<th>Evaluable patients&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Confirmed CR/PR</th>
<th>CR/PR (too early to be confirmed)</th>
<th>ORR % (n/N) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>50% (3/6) (12-88)</td>
</tr>
<tr>
<td>6</td>
<td>19</td>
<td>4</td>
<td>1</td>
<td>26% (5/19) (9-51)</td>
</tr>
<tr>
<td>8</td>
<td>60</td>
<td>13</td>
<td>2</td>
<td>25% (15/60) (15-38)</td>
</tr>
<tr>
<td>Total</td>
<td>85</td>
<td>20</td>
<td>3</td>
<td>27% (23/85) (18-38)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Includes patients with ≥1 posttreatment scan or who discontinued treatment.
DS-1062 | Efficacy Results

Change in Tumor Burden by DS-1062 Dose by BICR

- 4 mg/kg (N=6)
- 6 mg/kg (N=19)
- 8 mg/kg (N=60)

Ongoing
Discontinued
Best Percentage Change in Sum of Longest Dimension From Baseline in Target Lesions by BICR, n=72

DS-1062 dose
- 4 mg/kg
- 6 mg/kg
- 8 mg/kg
**DS-1062 | Efficacy Results**

**Target Lesions After DS-1062 Treatment**

<table>
<thead>
<tr>
<th>Baseline CT</th>
<th>1st scan at 6 weeks</th>
</tr>
</thead>
</table>

65 yo female with lung adenocarcinoma and multiple abdominal metastases. Enrolled at 8 mg/kg, first 6-week scan demonstrating a 41% tumor reduction per RECIST 1.1, treatment 10 months.
7/23 responses are ‘delayed’, first observed after first imaging
Distribution of TROP2 H-Score (Left) and Boxplot of TROP2 H-Score (Right) by Response (BICR)

*Patients were included in the histogram only if tumor biopsy was evaluable.
CR, complete response; NE, nonevaluable; PD, progressive disease; PR, partial response; SD, stable disease.
**Ph1:** FIH in NSCLC  
Monotherapy dose escalation and expansion

**Ph2 Pivotal: NSCLC**  
Post platinum, chemotherapy and I/O

**Ph3 Pivotal: NSCLC**  
Possible TROP2 selection

**Ph2: Signal seeking: NSCLC w/ actionable mutations (EGFR, ALK, ROS1, NTRK, bRAF); post TKI/ chemo ± I/O**

**Ph1b Priority:** Safety w/ PD-1/L1 MAb  
X3 studies with different ICI

---

**Ph1 FIH NSCLC**  
4, 6, and 8 mg/kg

**Ph2 NSCLC w/o mut**  
Dose A and B

**Ph3 NSCLC w/o mut**  
DS-1062 vs SOC

**Ph2 NSCLC w/ mut**  
Dose A and B

**Ph1b NSCLC w/ I/O (X3 studies)**  
DS-1062 @ Dose A, B, C
DS-1062 | What Does It Mean?

- 27+% ORR in unselected last-line, post platinum (91%) and post I/O (88%) NSCLC
- Includes complete responses (CR’s) by Independent Review
- Durability of response, continued tumor control and late occurring responses are unique features
- Active dose range covers 4 to 8 mg/kg, leaving plenty of room to define best justifiable dose
- Clear fast to market path, and focus on NSCLC (all comers, activating mutation post TKI, earlier lines in combination with I/O)
- Plan to initiate study in TNBC by year end
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan

6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
CE-Alpha Portfolio Strategy

◆ Embrace String of Pearls strategy
  • Maintain healthy development flow of high value drug candidates
  • Identify and rapidly scale up/accelerate any higher value drug candidate ("à la DS-8201")

◆ Maximize the intrinsic quality/value of the pearls
  • Secure and progress competitive advantage of our multiple ADC platforms
  • Focus on high unmet need and thorough prioritization for First In Class/Best In Class that can change SOC
  • Deliver fast POP (Proof of Principle), POM (Proof of Mechanism) with early involvement of the US and Japan (at FTIH stage)

◆ Maximize value of the portfolio
  • Rigorous assessment using the 5R’s grid for each asset, and 5R’s heat map for portfolio\(^1,2\)
  • Rigorous prioritization, allocating resources and risk as a function of expected value
  • Rigorous value generation: deliver value of unique science & technology portfolio and supplement as needed through proactive screening of in-licensing drug candidates

Deliver *string of pearls* NMEs

**Hybrid model** of internal and external collaborative development

Enhancing strong Ph 1 capabilities in the US; establish in EU

- 4th and 5th DXd ADC in clinical testing (DS-7300 B7H3; DS-6157 GPR20 for GIST)
- ~ High single digit of First-Time-in-Human studies planned through FY 2021; ~one-half ADCs
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan
6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
Entered into an exceptional agreement with Syneos Health to quickly scale up operational capabilities, driving our leading ADCs forward through regulatory approvals.

Enables earlier engagement of Syneos Health with the Global Project Team on study design, and in-line with a quality delivery process for effective end-to-end clinical development.

Expect deeper synergies at the clinical investigational site level.

Allows us to simultaneously develop our oncology capabilities with a focus on site engagement.
An Exceptional Partnership

Collaborate and leverage each other’s strengths to deliver the 3 leading ADC assets in the portfolio faster

MISSION A coalition bringing together one team, that deploys the industry leading Oncology asset development model focusing on quality delivery and site engagement to accelerate access for patients and optimize value
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan
6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
SARS-CoV-2 Pandemic | Enrollment Impact – Key Studies

DESTINY-Breast02 Global Enrollment
- MONTHLY Actuals

DESTINY-Breast03 Global Enrollment
- MONTHLY Actuals

DESTINY-Breast04 Global Enrollment
- MONTHLY Actuals

DS1062-A-J101 Global Enrollment
- MONTHLY Actuals
DS-8201 DESTINY
◆ ~70% of sites closed to monitoring, ~23% sites have screening and/or enrollment on hold, **1.4%** sites with subject dosing at risk
◆ We now project **1 to 2 months impact overall on time to completing studies**
◆ Remote monitoring and oversight as a new norm – still adjusting to meet oversight and quality needs
◆ Some sites in EU (e.g., France, Italy, Belgium, Austria) are expected to re-open monitoring imminently

DS-1062
◆ Short-term data delivery only marginally affected / new studies start-up NOT affected

All ADC programs
◆ **COVID-19-related protocol deviations: none to date substantially impact study integrity**
  • Longitudinal monthly serum banking will allow retrospective identification of SARS-CoV2 infection, as a contributing and/or risk factor for adverse event
  • Missing some research tumor sample acquisition, for precision medicine intense trials (may lead to adding more subjects in some early phase studies to recover the right number of needed samples)
◆ **Roll out of next wave studies**, most importantly DS-1062 and DS-8201 **not substantially affected**
Today’s Agenda

1. Introduction
2. DS-8201: The Value
3. DS-8201: The Data
4. DS-8201: The Plan
5. DS-1062: The Data & The Plan
6. Alpha
7. R&D Transformation
8. SARS-CoV-2 Pandemic Impact
9. News Flow and Future Events
## News Flow and Future Events (as of May 31, 2020)

| **Trastuzumab Deruxtecan (DS-8201)** | **DESTINY-Breast01**: Pivotal phase 2 HER2 positive metastatic breast cancer (mBC) study  
- EU Submission: On Track for 1H FY2020  
**DESTINY-Gastric01**: Pivotal phase 2 HER2 positive metastatic gastric cancer study  
- Japan approval: Anticipated for Q3 FY2020  
- Discussions underway with additional global health authorities |
| **DS-1062** | **Pivotal Phase 2 study**: Non-small cell lung cancer (NSCLC) with no actionable mutations  
- Global Initiation: Anticipated for 2H FY2020  
**Phase 1 IO Combination Studies**: Planned start for 2H FY2020 |
| **U3-1402** | **Phase 1 study**: EGFR mutated NSCLC  
- Updated data planned for ESMO 2020  
**Phase 1/2 study**: HER3 positive mBC  
- Updated data planned for SABCS 2020  
**Phase 1 EGFR TKI Combination Study**: Planned start for 2H FY2020 |
| **Valemotostat (DS-3201)** | **Phase 1 study**: Peripheral T-Cell Lymphoma (PTCL)  
- Updated data planned for future scientific meeting  
**Pivotal Phase 2 study**: PTCL – Planned start for 2H FY2020 |
| **Axi-Cel™** | **Phase 2**: B-cell Lymphoma  
- Japan approval: Anticipated for Q3 FY2020 |
| **DS-1647 (G47Δ)** | **Phase 2**: Malignant Glioma  
- Japan Submission: NDA planned 1H FY2020 |
Daiichi Sankyo Co., Ltd.
Corporate Communications Dept.

TEL: +81-3-6225-1126
Email: DaiichiSankyoIR@daiichisankyo.co.jp